Medline Inc. is under investigation by Kaplan Fox & Kilsheimer LLP for potential securities violations following an FDA warning about significant manufacturing practice violations. The FDA highlighted failures in investigating discrepancies and microbial contamination in Medline's pharmaceutical products. This led to a 7.16% drop in Medline's stock price on June 2, 2026. The investigation could impact investor confidence and lead to legal actions against the company.
Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
The Phase 3 ALKIVIA study by argenx demonstrated that efgartigimod significantly improved symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). The study met its primary and key...
Uber Technologies is falling behind competitors Waymo and Tesla in the U.S. robotaxi market, projecting only 2,000 robotaxis by 2027 compared to Waymo's 20,000 and Tesla's plans for millions. The company's revenue growth is slowing, with Q3 growth un...
Bitcoin's total mining hashrate has rebounded above one zettahash over the past week, signaling renewed strength in the network's mining competition. This recovery suggests that recent exits by some mining companies do not indicate an overall decline...
